20+ Years of Experience
We have in-depth experience in viral vectors development and manufacturing.
2 Successful FDA Inspections
Our sites passed multiple Pre-Approval Inspections for cell and gene products commercialization successfully.
Significant Investments
We continue to invest in viral technologies and innovation.
Flexible Operational Models
We provide flexible operating models for manufacturing as well as dedicated suites.
Available Capacity
We can offer additional expansion space as required.
Dedicated Regulatory Experts
We offer phase-appropriate support to secure and speed-up your product's journey to commercialization.
A streamlined platform
Our platform utilizes our established and ready-to-use proprietary cell lines and plasmids for AAV production; pre-qualified assays from our library; robust and optimized unit operations; ready to go tech-transfer documentation.
A de-risked path to commercialization
Our standardized, systematic approach to tech transfers, manufacturing and pre-approval inspection readiness, leveraging our established global quality and regulatory infrastructure will de-risk your journey to commercialization.
Commercial viability
We enable commercial viability using a platform with high AAV productivity through our proprietary cell line and plasmids. Availability of analytics to optimize full vs empty capsids early in process development. Flexible cGMP capacity and operational models are available to support variable demand.

High Performing Production Host Cell Line and Plasmids


At the heart of our robust processes is our Xcite® AAV Transient Expression platform. Lonza's proprietary Production Host Cell Line and AAV Production Plasmids were developed based on our experience of the needs of developers of gene therapies.


Now Available to Take to Your Laboratory

5B8 Production Host Cell Line

  • Suspension HEK293 cell line
  • High AAV productivity for multiple serotypes and GOIs
  • Proven scalability for AAV production
  • Research and cGMP cell banks available under license

AAV Production Plasmids

  • Proprietary know-how on pHelper plasmid and promoter for balanced Rep/Cap expression
  • Higher productivity and titers1
  • Optimized for multiple AAV serotypes and GOIs

1 Lonza in-house data, comparison to standard commercially available plasmids.


Improve your AAV manufacturing process

To bring our platform to your laboratory, you can license our AAV platform components by emailing VVET@lonza.com

Learn more about our end-to-end cell & gene therapy services.